<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25993594</article-id><article-id pub-id-type="pmc">4415867</article-id><article-id pub-id-type="doi">10.5935/abc.20140205</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute
Decompensated Heart Failure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Jo&#x000e3;o Pedro</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>M&#x000e1;rio</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Oliveira</surname><given-names>Jos&#x000e9; Carlos</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Marques</surname><given-names>Irene</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Bettencourt</surname><given-names>Paulo</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Carvalho</surname><given-names>Henrique</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib></contrib-group><aff id="aff01"><label>1</label> Centro Hospitalar do Porto, Porto &#x02013; Portugal</aff><aff id="aff02"><label>2</label> Centro Hospitalar S&#x000e3;o Jo&#x000e3;o, Porto &#x02013; Portugal</aff><author-notes><corresp id="c01"><bold>Mailing Address: Jo&#x000e3;o Pedro Ferreira,</bold> Rua Dr.
Jos&#x000e9; Oliveira e Silva, n&#x000ba; 52, Salreu-Estarreja. Postal Code 3865-209,
Porto &#x02013; Portugal. Email: <email>jp7ferreira@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>4</month><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>4</month><year>2015</year></pub-date><volume>104</volume><issue>4</issue><fpage>308</fpage><lpage>314</lpage><history><date date-type="received"><day>26</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>27</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Matrix metalloproteinases (MMPs) are a family of enzymes important for the
resorption of extracellular matrices, control of vascular remodeling and repair.
Increased activity of MMP2 has been demonstrated in heart failure, and in acutely
decompensated heart failure (ADHF) a decrease in circulating MMPs has been
demonstrated along with successful treatment.</p></sec><sec><title>Objective</title><p>Our aim was to test the influence of spironolactone in MMP2 levels.</p></sec><sec><title>Methods</title><p>Secondary analysis of a prospective, interventional study including 100 patients
with ADHF. Fifty patients were non-randomly assigned to spironolactone (100
mg/day) plus standard ADHF therapy (spironolactone group) or standard ADHF therapy
alone (control group).</p></sec><sec><title>Results</title><p>Spironolactone group patients were younger and had lower creatinine and urea
levels (all p &#x0003c; 0.05). Baseline MMP2, NT-pro BNP and weight did not differ
between spironolactone and control groups. A trend towards a more pronounced
decrease in MMP2 from baseline to day 3 was observed in the spironolactone group
(-21 [-50 to 19] vs 1.5 [-26 to 38] ng/mL, p = 0.06).
NT-pro BNP and weight also had a greater decrease in the spironolactone group. The
proportion of patients with a decrease in MMP2 levels from baseline to day 3 was
also likely to be greater in the spironolactone group (50% vs 66.7%), but without
statistical significance. Correlations between MMP2, NT-pro BNP and weight
variation were not statistically significant.</p></sec><sec><title>Conclusion</title><p>MMP2 levels are increased in ADHF. Patients treated with spironolactone may have a
greater reduction in MMP2 levels.</p></sec></abstract><kwd-group><kwd>Heart Failure</kwd><kwd>Spironolactona/therapeutic use</kwd><kwd>Matrix Metalloproteinase 2/ therapeutic use</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Matrix metalloproteinases (MMPs) are a family of zinc-dependent interstitial enzymes
important for the resorption of extracellular matrices (ECM) in both health and
disease<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. extracellular matrices
are a dynamic structure central to the control of vascular remodeling and
repair<sup><xref rid="r01" ref-type="bibr">1</xref></sup>, mostly due to the
ability of MMPs to reabsorb and digest excessive amounts of ECM responsible for
structural disruption<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup>.</p><p>Elevated MMPs promote loss of cardiac contractility via cell proteolysis and alterations
in the ECM, contributing to cardiac and extra-cardiac remodeling processes<sup><xref rid="r04" ref-type="bibr">4</xref></sup>. In fact, clinical and experimental heart
failure (HF) models of dilated and ischemic cardiomyopathy have demonstrated an
increased activity of matrix metalloproteinase-2 (MMP2)<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r05" ref-type="bibr">5</xref>-<xref rid="r07" ref-type="bibr">7</xref></sup>. In patients with HF, increased levels of MMP2 were
associated with all-cause mortality<sup><xref rid="r08" ref-type="bibr">8</xref></sup>.
Concordantly, in the acutely decompensated heart failure (ADHF) setting a decrease of
circulating MMPs has been demonstrated along with successful ADHF treatment<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup>.
Previous studies have suggested a therapeutic benefit of spironolactone in ADHF
setting<sup><xref rid="r10" ref-type="bibr">10</xref></sup>. But no studies had
looked to the effect of spironolactone in the ECM remodeling.</p><p>In the present study, we aimed to examine the influence of spironolactone on the ECM
remodeling in ADHF patients. We hypothesized that MMP-2 plasma levels of ADHF patients
will have a steeper decrease if spironolactone is added to standard treatment.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Design</title><p>We analyzed data from a previous pilot, prospective, interventional, clinical trial
that we performed between February 2012 and February 2013. During that period, we
enrolled 100 consecutive patients who presented at a Portuguese tertiary hospital
with ADHF. Patients were eligible for enrollment if they had decompensation of
chronic HF with symptoms leading to hospitalization. ADHF was diagnosed based on a
history of chronic HF and at least one acute symptom (dyspnea, orthopnea, or edema)
and one sign (rales, peripheral edema, ascites, or pulmonary vascular congestion on
chest radiography). Patients were non-randomly assigned in a sequential 1:1 ratio to
spironolactone plus standard ADHF therapy or standard ADHF therapy alone, 50 patients
in each arm. Patients were alternately assigned to the spironolactone arm or the
standard ADHF therapy arm in a sequential manner - the first patient to one arm and
the next to the other arm. This sequence was repeated until we reached 100 patients,
50 in the spironolactone group and 50 in the control group. Patients were blinded to
the allocation, but the clinicians were not. The recommended spironolactone dose was
100 mg/day. However, the attending physician could decrease that dose to 50 mg/day
after 48h upon admission. Furosemide dose and route of administration were clinically
adjusted according to the patients' hydration status.</p><p>Exclusion criteria were: chronic use of mineralocorticoid receptor antagonists;
cardiac surgery within 60 days of enrollment; cardiac mechanical support; cardiac
resynchronization-therapy within the last 60 days; comorbid conditions with an
expected survival of less than 6 months; acute myocardial infarction at time of
hospitalization; uncorrected hemodynamically significant primary cardiac valvular
disease; patients requiring intravenous vasodilators or inotropic agents; supine
systolic arterial blood pressure &#x0003c; 90 mmHg; plasma creatinine level &#x0003e; 1.5
mg/dL; serum potassium level &#x0003e; 5.0 mmol/L; hemoglobin level &#x0003c; 9 g/dL; and
sepsis.</p><p>Institutional review board or ethics committee approval was obtained. All patients
provided written informed consent to participate in the study.</p></sec><sec><title>Clinical assessment of participants</title><p>Patients' clinical status, including physical examination, was prospectively recorded
by the same attending physician on day 1 and day 3. Medications and respective
dosages were prospectively recorded by the investigators according to the attending
physician prescriptions.</p><p>Blood samples were collected in the first 24 hours after the patient's admission
(baseline) to the hospital, and day-3 samples were collected between 72 and 96 hours
of hospitalization. Samples were analyzed at a central core laboratory, and included
plasma creatinine and urea, electrolytes, NT-pro BNP and MMP2. Clinical assessment
and routine analyses were performed daily during hospital stay. Estimated glomerular
filtration rate (eGFR) was determined using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation<sup><xref rid="r11" ref-type="bibr">11</xref></sup>.
All patients performed a transthoracic echocardiography within 72 hours from
admission. Left ventricular ejection fraction (LVEF) was calculated according to
biplane Simpson method.</p><p>MMP2 was measured by using enzyme-linked immunosorbent assays (ELISA) - Quantikine
Elisa Human MMP-2 Immunoassay (R&#x00026;D Systems, Inc&#x000ae;). The normal range of
MMP2 values published by the manufacturer, expressed as median [interquartile
range<sub>25-75</sub>, IQR<sub>25-75</sub>], is 199 [161 -
301] ng/mL. The assay sensitivity is 0.047 ng/mL.</p><p>Of the 100 studied patients we analyzed baseline (day 1) and day 3 blood samples from
87. Thirteen samples were not analyzed due to transport and/or sampling processing
errors. Samples were collected in the morning with patients supine. Serum was
separated and stored at -80 &#x000ba;C until sample analysis.</p></sec><sec><title>Variable definitions</title><p>We classified patients according to spironolactone use and their response to diuretic
therapy.</p><p>We studied the relationships between baseline characteristics, day 3 and changes
(&#x02206;, difference between day 3 and baseline values) in MMP2, NT-proBNP and
weight regarding the spironolactone use and diuretic response.</p></sec><sec><title>Statistical Analysis</title><p>Normally distributed continuous variables are expressed as mean &#x000b1; standard
deviation (SD), and skewed distributions are presented as median
[IQR<sub>25-75</sub>].</p><p>Categorical variables are expressed in proportions (%).</p><p>Comparison between groups was performed using parametric (independent samples
t-test), non-parametric (Mann-Whitney test), or Chi-square tests, as appropriate.</p><p>Correlations of MMP2 were examined by single variable linear regression and presented
as correlation coefficient and 95% confidence interval (95% CI).</p><p>A p value &#x0003c; 0.05 was considered statistically significant.</p><p>Statistical analysis was performed using SPSS software, version 19 (Chicago, IL,
USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Baseline Characteristics in Control and Spironolactone Groups</title><p>Control group patients were older (78.8 &#x000b1; 9.3 versus [vs.] 73.2
&#x000b1; 11.7 years, p = 0.01), and had higher creatinine and urea levels (1.15
&#x000b1; 0.27 vs. 1.03 &#x000b1; 0.30 mg/dL, p = 0.026 and 59.32 &#x000b1; 22.27 vs.
51.10 &#x000b1; 18.63 mg/dL, p = 0.048). No differences between groups were found
regarding the following variables: sex; diabetes mellitus; chronic obstructive
pulmonary disease; dementia; sleep apnea; non-invasive ventilation; ischemic heart
disease; atrial fibrillation; LVEF; weight; systolic blood pressure; potassium;
sodium; hemoglobin; albumin; NT-pro BNP; MMP2; furosemide dose; hospital length of
stay; and the proportion of patients on angiotensin converting enzyme inhibitors and
beta-blockers (<xref ref-type="table" rid="t01">Table 1</xref>).</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline population characteristics, laboratory results, medications, and
hospital length of stay in treatment and control groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1"><bold>Control Group (n = 50)</bold></th><th align="center" rowspan="1" colspan="1"><bold>Spironolactone Group (n = 50)</bold></th><th align="center" rowspan="1" colspan="1"><bold>p Value</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (yrs)</td><td align="center" rowspan="1" colspan="1">78.8 &#x000b1; 9.3</td><td align="center" rowspan="1" colspan="1">73.2 &#x000b1; 11.7</td><td align="center" rowspan="1" colspan="1">0.010</td></tr><tr><td rowspan="1" colspan="1">Male Sex - %</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">0.31<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Diabetes Mellitus - %</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0.31<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Chronic Obstructive Pulmonary Disease - %</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">0.32<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Dementia - %</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">0.22<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Sleep Apnea - %</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">0.32<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Non-Invasive Ventilation - %</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">0.42<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Ischemic Heart Disease -%</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">0.69<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Atrial Fibrillation - %</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0.07<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Left Ventricular Ejection Fraction &#x0003c; 40% - %</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">0.22<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Weight (Kg)</td><td align="center" rowspan="1" colspan="1">75.6 &#x000b1; 16.3</td><td align="center" rowspan="1" colspan="1">76.1 &#x000b1; 16.4</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1">Systolic Blood Pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">140.5 &#x000b1; 23.9</td><td align="center" rowspan="1" colspan="1">139 &#x000b1; 27.9</td><td align="center" rowspan="1" colspan="1">0.80</td></tr><tr><td rowspan="1" colspan="1">Plasma Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">1.15 &#x000b1; 0.27</td><td align="center" rowspan="1" colspan="1">1.03 &#x000b1; 0.30</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td rowspan="1" colspan="1">eGFR (mL/min/1,73 m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">54.5 &#x000b1; 16.5</td><td align="center" rowspan="1" colspan="1">68.3 &#x000b1; 23.6</td><td align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">Plasma Urea (mg/dL)</td><td align="center" rowspan="1" colspan="1">59.3 &#x000b1; 22.3</td><td align="center" rowspan="1" colspan="1">51.1 &#x000b1; 18.6</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td rowspan="1" colspan="1">Serum Potassium (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.1 &#x000b1; 0.4</td><td align="center" rowspan="1" colspan="1">4.0 &#x000b1; 0.6</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td rowspan="1" colspan="1">Serum Sodium (mmol/L)</td><td align="center" rowspan="1" colspan="1">140.5 &#x000b1; 5.0</td><td align="center" rowspan="1" colspan="1">140.6 &#x000b1; 3.7</td><td align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" rowspan="1" colspan="1">12.2 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">12.7 &#x000b1; 2.3</td><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td rowspan="1" colspan="1">Albumin (mg/dL)</td><td align="center" rowspan="1" colspan="1">3.7 &#x000b1; 0.4</td><td align="center" rowspan="1" colspan="1">3.6 &#x000b1; 0.4</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td rowspan="1" colspan="1">NT-pro BNP (pg/mL)</td><td align="center" rowspan="1" colspan="1">3102 [1797 - 8204]</td><td align="center" rowspan="1" colspan="1">2701 [1463 - 5004]</td><td align="center" rowspan="1" colspan="1">0.17<xref ref-type="table-fn" rid="TFN01">*</xref></td></tr><tr><td rowspan="1" colspan="1">MMP2 (ng/mL)</td><td align="center" rowspan="1" colspan="1">260 [226 - 299]</td><td align="center" rowspan="1" colspan="1">268 [207 - 336]</td><td align="center" rowspan="1" colspan="1">0.52<xref ref-type="table-fn" rid="TFN01">*</xref></td></tr><tr><td rowspan="1" colspan="1">Intravenous Furosemide Dose (mg/d)</td><td align="center" rowspan="1" colspan="1">75.6 &#x000b1; 20.7</td><td align="center" rowspan="1" colspan="1">76.0 &#x000b1; 25.5</td><td align="center" rowspan="1" colspan="1">0.93</td></tr><tr><td rowspan="1" colspan="1">ACEi/ARB - %</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">0.20<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Beta-Blocker - %</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">0.30<xref ref-type="table-fn" rid="TFN02">**</xref></td></tr><tr><td rowspan="1" colspan="1">Spironolactone - %</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Spironolactone Dose (mg/d)</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">94.5 &#x000b1; 23.3</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">Hospital Length of Stay (days)</td><td align="center" rowspan="1" colspan="1">9.0 &#x000b1; 3.7</td><td align="center" rowspan="1" colspan="1">8.7 &#x000b1; 3.0</td><td align="center" rowspan="1" colspan="1">0.59</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are presented as mean &#x000b1; standard deviation
[SD], p value or median [interquartile range,
IQR], p value. Categorical variables are presented as absolute number
(%), p value.</p></fn><fn id="TFN01"><label>*</label><p>Non-parametric paired sample test;</p></fn><fn id="TFN02"><label>**</label><p>Chi-square test.</p></fn><fn><p>eGFR: estimated glomerular filtration rate; NT-pro BNP: N-terminal pro brain
natriuretic peptide; MMP2: matrix metalloproteinase -2; ACEi/ARB:
angiotensinconverting enzyme inhibitors/angiotensin receptor blockers.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Spironolactone Influence on MMP2, NT-pro BNP and Weight Dynamic Changes</title><p>No differences between control and spironolactone groups were observed regarding
baseline and day 3 MMP2 levels (<xref ref-type="table" rid="t02">Table 2</xref>).
However, MMP2 decreased from baseline to day 3 in the spironolactone group, while, in
control group, MMP2 levels increased, leading to a tendency towards a reduction in
MMP2 levels in the spironolactone group (1.5 [-26 to 38] vs. -21
[-50 to 19] ng/mL, p = 0.06) (<xref ref-type="table" rid="t02">Table
2</xref> and <xref ref-type="fig" rid="f01">Figure 1</xref>). The proportion of
patients showing a decrease in MMP2 levels from baseline to day 3 was also greater in
the spironolactone group. That difference, however, did not reach statistical
significance: 21 control patients (50%) vs. 30 spironolactone group patients (66.7%),
p = 0.115.</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Comparison of &#x02206; MMP2 Levels from baseline to day 3 between control and
spironolactone groups. A trend towards a more pronounced reduction in MMP2
levels was observed in spironolactone group. Analysis was performed comparing
the variation (&#x02206;, day 3 - baseline) of MMP2 levels between control and
spironolactone groups using non-parametric independent sample tests (1.5
[-26 to 38] versus -21 [-50 to 19], p = 0.06).</p><p>Legend: MMP2 = matrix metalloproteinase-2.</p></caption><graphic xlink:href="abc-104-04-0308-g01"/></fig><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of MMP2, NT-pro BNP and weight at baseline, day 3, and change
(Delta, &#x02206;) between the study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1"><bold>Control Group</bold></th><th align="center" rowspan="1" colspan="1"><bold>Spironolactone Group</bold></th><th align="center" rowspan="1" colspan="1"><bold>p Value</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">MMP2</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">260 [226 - 299]</td><td align="center" rowspan="1" colspan="1">268 [207 - 336]</td><td align="center" rowspan="1" colspan="1">0.52<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td rowspan="1" colspan="1">Day 3</td><td align="center" rowspan="1" colspan="1">266 [227 - 298]</td><td align="center" rowspan="1" colspan="1">261 [212 - 307]</td><td align="center" rowspan="1" colspan="1">0.49<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02206; (day 3 - baseline)</td><td align="center" rowspan="1" colspan="1">1.5 [-26 to 38]</td><td align="center" rowspan="1" colspan="1">-21 [-50 to 19]</td><td align="center" rowspan="1" colspan="1">0.06<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">NT-pro BNP</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">3102 [1792 - 8204]</td><td align="center" rowspan="1" colspan="1">2701 [1463 - 5004]</td><td align="center" rowspan="1" colspan="1">0.17<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td rowspan="1" colspan="1">Day 3</td><td align="center" rowspan="1" colspan="1">2488 [923 - 5502]</td><td align="center" rowspan="1" colspan="1">1555 [722 - 2554]</td><td align="center" rowspan="1" colspan="1">0.05<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x02206; (day 3 - baseline)</td><td align="center" rowspan="1" colspan="1">-945 [-2249 to -62]</td><td align="center" rowspan="1" colspan="1">-816 [-1833 to -106]</td><td align="center" rowspan="1" colspan="1">0.75<xref ref-type="table-fn" rid="TFN03">*</xref></td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Weight</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Baseline</td><td align="center" rowspan="1" colspan="1">75.6 &#x000b1; 16.3</td><td align="center" rowspan="1" colspan="1">76.1 &#x000b1; 16.4</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr><td rowspan="1" colspan="1">Day 3</td><td align="center" rowspan="1" colspan="1">72.8 &#x000b1; 16.3</td><td align="center" rowspan="1" colspan="1">71.3 &#x000b1; 16.2</td><td align="center" rowspan="1" colspan="1">0.66</td></tr><tr><td rowspan="1" colspan="1">&#x02206; (day 3 - baseline)</td><td align="center" rowspan="1" colspan="1">-2.9 &#x000b1; 2.4</td><td align="center" rowspan="1" colspan="1">-4.8 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are presented as mean &#x000b1; standard deviation
[SD], p value or median [interquartile range,
IQR], p value, and independent sample t-test or independent sample
non-parametric test were used, respectively.</p></fn><fn id="TFN03"><label>*</label><p>non-parametric test.</p></fn><fn><p>NT-pro BNP: N-terminal pro brain natriuretic peptide; MMP2: matrix
metalloproteinase -2; A: delta or difference between day 3 and baseline
values.</p></fn></table-wrap-foot></table-wrap><p>No differences were observed in NT-pro BNP levels at baseline. However, on day 3, the
spironolactone group patients showed lower levels of NT-pro BNP (248 [923 -
5502] vs. 1555 [722 - 2554] pg/mL, p = 0.05). No differences
between groups were observed in the variation of NT-pro BNP levels probably due to
the lower levels (although not significantly lower) of NT-pro BNP at baseline in the
spironolactone group, leading to a smaller amplitude of variation in this group
(<xref ref-type="table" rid="t02">Table 2</xref>).</p><p>A greater weight decrease was also observed in the spironolactone-treated patients
(-2.9 &#x000b1; 2.4 vs. -4.8 &#x000b1; 2.8 kg, p &#x0003c; 0.001) (<xref ref-type="table" rid="t02">Table 2</xref>).</p></sec><sec><title>&#x02206; MMP2, &#x02206; NT-pro BNP and &#x02206; Weight Correlations</title><p>No significant correlations were observed between &#x02206; in MMP2, NT-pro BNP and
weight (<xref ref-type="table" rid="t03">Table 3</xref>).</p><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Correlation coefficients and 95% confidence intervals (CI) between delta
(&#x02206;) MMP2, &#x02206; NT-pro BNP, and &#x02206; weight</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th rowspan="1" colspan="1"><bold>&#x02206; MMP2 Correlation Coefficient</bold></th><th rowspan="1" colspan="1"><bold>95%CI</bold></th><th rowspan="1" colspan="1"><bold>p Value</bold></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">&#x02206; NT-pro BNP</td><td rowspan="1" colspan="1">0.11</td><td rowspan="1" colspan="1">-0.003 to 0.01</td><td rowspan="1" colspan="1">0.33</td></tr><tr><td rowspan="1" colspan="1">&#x02206; Weight</td><td rowspan="1" colspan="1">0.12</td><td rowspan="1" colspan="1">-1.97 to 7.05</td><td rowspan="1" colspan="1">0.27</td></tr></tbody></table><table-wrap-foot><fn><p>MMP2: matrix metalloproteinase-2; NT-pro BNP: N-terminal pro-brain
natriuretic peptide; &#x02206;: delta or difference between day 3 and
baseline values.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study we observed increased baseline levels of MMP2 in patients with
ADHF. The patients treated with spironolactone showed a tendency towards a greater
reduction in MMP2 levels. These results are consistent with previous findings
demonstrating the impact of mineralocorticoid receptor antagonists on the ECM remodeling
and highlight the potential interest about spironolactone for the treatment of ADHF,
where those mechanisms are strongly exacerbated.</p><p>Increased serum levels of MMP2 have been demonstrated in the ADHF setting<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup>.
In our study, the median [IQR] MMP2 levels at admission were 260
[225 - 312] ng/mL. These values are above the normal range defined by the
manufacturer, 199 [161 - 301] ng/mL, and are in accordance with previous
reports on patients with HF decompensation. A previous study by Shirakabe A. et
al<sup><xref rid="r03" ref-type="bibr">3</xref></sup> has also shown increased
serum MMP2 levels in ADHF, with a rapid decrease along with HF compensation.
Furthermore, an interventional placebo-controlled trial performed by Tziakas DN. et
al<sup><xref rid="r09" ref-type="bibr">9</xref></sup> has shown a significant
reduction in MMP2 levels in the group of patients treated with levosimendan. In animal
models, exacerbated neurohormonal activation leads to an increase in the levels of
several myocardial MMP subtypes<sup><xref rid="r12" ref-type="bibr">12</xref>-<xref rid="r14" ref-type="bibr">14</xref></sup>. MMPs are important for the proteolysis
that can affect the composition of ECM and, consequently, myocardial remodeling.
Additionally, increased ECM turnover may be associated with pathological myocardial
remodeling, which may be accelerated in decompensated HF<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r15" ref-type="bibr">15</xref></sup>. Consequently,
a reduction in markers of ECM turnover may serve as a surrogate marker for deceleration
of myocardial turnover and remodeling. Our study showed a greater decrease of MMP2 in
the group of patients submitted to spironolactone treatment. Mineralocorticoid receptor
antagonists improve survival and reduce morbidity in patients with HF and reduced
ejection fraction and mild-to-severe symptoms, and in patients with left ventricular
systolic dysfunction and HF after acute myocardial infarction<sup><xref rid="r16" ref-type="bibr">16</xref>-<xref rid="r18" ref-type="bibr">18</xref></sup>. Additionally,
used in natriuretic doses, mineralocorticoid receptor antagonists are likely to improve
congestion in ADHF with good tolerability and few side effects<sup><xref rid="r19" ref-type="bibr">19</xref></sup>. Several proposed mechanisms explain how
mineralocorticoid receptor antagonists improve HF outcomes, and these pathways include a
reduction in myocardial remodeling<sup><xref rid="r20" ref-type="bibr">20</xref></sup>.
Our study provides important information on a better understanding of ECM turnover
processes. The steeper MMP2 reduction observed in patients submitted to spironolactone
treatment provides a real demonstration of potential mitigation of harmful remodeling
through spironolactone use. Interestingly, patients without MMP2 reduction or increase,
after an acute HF episode, had poorer prognosis<sup><xref rid="r03" ref-type="bibr">3</xref></sup>. Therefore, changes in MMP2 levels are a potentially useful
prognostic marker in patients admitted due to ADHF.</p><p>NT-pro BNP is a well-validated, widely used, and very accurate biomarker for the
diagnosis and risk stratification of HF<sup><xref rid="r21" ref-type="bibr">21</xref></sup>. Patients submitted to spironolactone treatment had lower levels of
NT-pro BNP on day 3, and a more pronounced weight reduction when compared to controls,
while patients with slower diuretic response had higher NT-pro BNP levels on day 3 of
hospitalization, a tendency towards lower NT-pro BNP reduction, and less weight loss.
However, the changes in MMP2 values did not correlate with the variation in NT-pro BNP
or weight. The small sample size, the NT-pro BNP and MMP2 elevated variance, and the
different mechanisms influencing those biomarkers may all explain the lack of
correlation.</p><p>Several limitations in our study should be noted. First, this was a single-centre,
non-randomized trial with a small number of patients with mixed HF etiologies and
treatments. Second, this post-hoc analysis has limitations inherent to observational
studies. Third, the decision to withdraw diuretic therapy was based on subjective
assessment of congestive signs and symptoms, so we cannot rule out the inter-observer
variability. However, in real life, the decision to step down diuretic therapy is also
based on subjective clinical evaluation. Fourth, our study excluded HF patients with
significant renal impairment, since plasma creatinine level lower than 1.5 mg/dL was an
inclusion criterion, leading to a potential selection of a subset of low-risk patients,
which can affect the external validity of our results. Fifth, the spironolactone group
patients were younger and had lower plasma creatinine and urea levels, which can
positively affect the response to that drug. Finally, only MMP2 was evaluated, and other
forms of MMPs may have different effects and responses in ADHF patients.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>The present study showed that MMP2 levels can be increased in ADHF, and that patients
treated with spironolactone may have a greater reduction in MMP2 levels. Whether these
findings have prognostic significance requires further investigation.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Author contributions</bold></p><p>Conception and design of the research, Acquisition of data, Statistical analysis and
Writing of the manuscript: Ferreira JP; Analysis and interpretation of the data:
Ferreira JP, Santos M, Oliveira JC, Bettencourt P; Obtaining financing: Carvalho H;
Critical revision of the manuscript for intellectual content: Ferreira JP, Santos M,
Marques I, Bettencourt P, Carvalho H.</p></fn><fn fn-type="conflict"><p><bold>Potential Conflict of Interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="supported-by"><p><bold>Sources of Funding</bold></p><p>This study was partially funded by Johnson &#x00026; Johnson.</p></fn><fn fn-type="other"><p><bold>Study Association</bold></p><p>This article is part of the thesis of Doctoral submitted by Jo&#x000e3;o Pedro
Ferreira, from Centro Hospitalar do Porto.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors acknowledge the lab technicians, especially Mr. Fernando Santos, for
technical assistance, and all physicians collaborating in the study.</p></ack><ref-list><title>References</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dollery </surname><given-names>CM</given-names></name><name><surname>McEwan</surname><given-names>JR</given-names></name><name><surname>Henney</surname><given-names>AM</given-names></name></person-group><article-title>Matrix metalloproteinases and cardiovascular disease</article-title><source>Circ Res.</source><year>1995</year><volume>77</volume><issue>5</issue><fpage>863</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">7554139</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altieri</surname><given-names>P</given-names></name><name><surname>Brunelli</surname><given-names>C</given-names></name><name><surname>Garibaldi</surname><given-names>S</given-names></name><name><surname>Nicolino</surname><given-names>A</given-names></name><name><surname>Ubaldi</surname><given-names>S</given-names></name><name><surname>Spallarossa</surname><given-names>P</given-names></name><etal/></person-group><article-title>Metalloproteinases 2 and 9 are increased in plasma of patients with
heart failure</article-title><source>Eur J Clin Invest</source><year>2003</year><volume>33</volume><issue>8</issue><fpage>648</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">12864774</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirakabe</surname><given-names>A</given-names></name><name><surname>Asai</surname><given-names>K</given-names></name><name><surname>Hata</surname><given-names>N</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Shinada</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Clinical significance of matrix metalloproteinase (MMP)-2 in patients
with acute heart failure</article-title><source>Int Heart J</source><year>2010</year><volume>51</volume><issue>6</issue><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">21173516</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouet-Benzineb</surname><given-names>P</given-names></name><name><surname>Buhler</surname><given-names>JM</given-names></name><name><surname>Dreyfus</surname><given-names>P</given-names></name><name><surname>Delcourt</surname><given-names>A</given-names></name><name><surname>Dorent</surname><given-names>R</given-names></name><name><surname>Perennec</surname><given-names>J</given-names></name><etal/></person-group><article-title>Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their
tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in
myosin-heavy chain degradation</article-title><source>Eur J Heart Fail</source><year>1999</year><volume>1</volume><issue>4</issue><fpage>337</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">10937947</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>SC</given-names></name><name><surname>Campbell</surname><given-names>SE</given-names></name><name><surname>Reddy</surname><given-names>HK</given-names></name><name><surname>Tjahja</surname><given-names>E</given-names></name><name><surname>Voelker</surname><given-names>DJ</given-names></name></person-group><article-title>Matrix metalloproteinase activity expression in infarcted,
noninfarcted and dilated cardiomyopathic human hearts</article-title><source>Mol Cell Biochem</source><year>1996</year><volume>155</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">8717434</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>CV</given-names></name><name><surname>Coker</surname><given-names>ML</given-names></name><name><surname>Zellner</surname><given-names>JL</given-names></name><name><surname>Handy</surname><given-names>JR</given-names></name><name><surname>Crumbley</surname><given-names>AJ</given-names><suffix>3rd</suffix></name><name><surname>Spinale</surname><given-names>FG</given-names></name></person-group><article-title>Increased matrix metalloproteinase activity and selective upregulation
in LV myocardium from patients with end-stage dilated
cardiomyopathy</article-title><source>Circulation</source><year>1998</year><volume>97</volume><issue>17</issue><fpage>1708</fpage><lpage>1715</lpage><pub-id pub-id-type="pmid">9591765</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinale</surname><given-names>FG</given-names></name><name><surname>Coker</surname><given-names>ML</given-names></name><name><surname>Heung</surname><given-names>LJ</given-names></name><name><surname>Bond</surname><given-names>BR</given-names></name><name><surname>Gunasenghe</surname><given-names>HR</given-names></name><name><surname>Etoh</surname><given-names>T</given-names></name><etal/></person-group><article-title>A matrix metalloproteinase induction/activation system exists in the
human left ventricular myocardium and is upregulated in heart
failure</article-title><source>Circulation</source><year>2000</year><volume>102</volume><issue>16</issue><fpage>1944</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">11034943</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>J</given-names></name><name><surname>Patal</surname><given-names>S</given-names></name><name><surname>Wexler</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><name><surname>Sheps</surname><given-names>D</given-names></name><name><surname>Keren</surname><given-names>G</given-names></name></person-group><article-title>Circulating matrix metalloproteinase-2 but not matrix
metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of
metalloproteinase-1 predicts outcome in patients with congestive heart
failure</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><issue>3</issue><fpage>484</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">16169329</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tziakas</surname><given-names>DN</given-names></name><name><surname>Chalikias</surname><given-names>GK</given-names></name><name><surname>Hatzinikolaou</surname><given-names>HI</given-names></name><name><surname>Stakos</surname><given-names>DA</given-names></name><name><surname>Papanas</surname><given-names>N</given-names></name><name><surname>Tentes</surname><given-names>IK</given-names></name><etal/></person-group><article-title>Levosimendan use reduces matrix metalloproteinase-2 in patients with
decompensated heart failure</article-title><source>Cardiovasc Drugs Ther</source><year>2005</year><volume>19</volume><issue>6</issue><fpage>399</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">16435069</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>JP</given-names></name><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Almeida</surname><given-names>S</given-names></name><name><surname>Marques</surname><given-names>I</given-names></name><name><surname>Bettencourt</surname><given-names>P</given-names></name><name><surname>Carvalho</surname><given-names>H</given-names></name></person-group><article-title>Tailoring diuretic therapy in acute heart failure: insight into early
diuretic response predictors</article-title><source>Clin Res Cardiol</source><year>2013</year><volume>102</volume><issue>10</issue><fpage>745</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">23839288</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Castro</surname><given-names>AF</given-names><suffix>3rd</suffix></name><name><surname>Feldman</surname><given-names>HI</given-names></name><etal/></person-group><article-title>A new equation to estimate glomerular filtration rate</article-title><source>Ann Intern Med</source><year>2009</year><volume>150</volume><issue>9</issue><fpage>604</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">19414839</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brilla</surname><given-names>CG</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Matsubara</surname><given-names>L</given-names></name><name><surname>Weber</surname><given-names>KT</given-names></name></person-group><article-title>Collagen metabolism in cultured adult rat cardiac fibroblasts:
response to angiotensin II and aldosterone</article-title><source>J Mol Cell Cardiol</source><year>1994</year><volume>26</volume><issue>7</issue><fpage>809</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">7966349</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coker</surname><given-names>ML</given-names></name><name><surname>Jolly</surname><given-names>JR</given-names></name><name><surname>Joffs</surname><given-names>C</given-names></name><name><surname>Etoh</surname><given-names>T</given-names></name><name><surname>Holder</surname><given-names>JR</given-names></name><name><surname>Bond</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase expression and activity in isolated myocytes
after neurohormonal stimulation</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>281</volume><issue>2</issue><fpage>H543</fpage><lpage>H551</lpage><pub-id pub-id-type="pmid">11454555</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>JT</given-names></name><name><surname>Hallak</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>O'Brien</surname><given-names>PM</given-names></name><name><surname>Sliskovic</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase inhibition attenuates left ventricular
remodeling and dysfunction in a rat model of progressive heart
failure</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>18</issue><fpage>2303</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11342481</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biolo</surname><given-names>A</given-names></name><name><surname>Fisch</surname><given-names>M</given-names></name><name><surname>Balog</surname><given-names>J</given-names></name><name><surname>Chao</surname><given-names>T</given-names></name><name><surname>Schulze</surname><given-names>PC</given-names></name><name><surname>Ooi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Episodes of acute heart failure syndrome are associated with increased
levels of</article-title><source>Circ Heart Fail</source><year>2010</year><volume>3</volume><issue>1</issue><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">19850700</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Remme</surname><given-names>WJ</given-names></name><name><surname>Cody</surname><given-names>R</given-names></name><name><surname>Castaigne</surname><given-names>A</given-names></name><name><surname>Perez</surname><given-names>A</given-names></name><etal/></person-group><article-title>The effect of spironolactone on morbidity and mortality in patients
with severe heart failure. Randomized Aldactone Evaluation Study
Investigators</article-title><source>N Engl J Med</source><year>1999</year><volume>341</volume><issue>10</issue><fpage>709</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">10471456</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Remme</surname><given-names>W</given-names></name><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Neaton</surname><given-names>J</given-names></name><name><surname>Martinez</surname><given-names>F</given-names></name><name><surname>Roniker</surname><given-names>B</given-names></name><etal/></person-group><article-title>Eplerenone, a selective aldosterone blocker, in patients with left
ventricular dysfunction after myocardial infarction</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>14</issue><fpage>1309</fpage><lpage>1321</lpage><pub-id pub-id-type="pmid">12668699</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Krum</surname><given-names>H</given-names></name><name><surname>van Velduisen</surname><given-names>DJ</given-names></name><name><surname>Swedberg K Shi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Eplerenone in patients with systolic heart failure and mild
symptoms</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><issue>1</issue><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21073363</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>JP</given-names></name><name><surname>Santos</surname><given-names>M</given-names></name><name><surname>Almeida</surname><given-names>S</given-names></name><name><surname>Marques</surname><given-names>I</given-names></name><name><surname>Bettencourt</surname><given-names>P</given-names></name><name><surname>Carvalho</surname><given-names>H</given-names></name></person-group><article-title>Mineralocorticoid receptor antagonism in acutely decompensated chronic
heart failure</article-title><source>Eur J Intern Med</source><year>2014</year><volume>25</volume><issue>1</issue><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24070521</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Gattis Stough</surname><given-names>W</given-names></name><name><surname>Rossignol</surname><given-names>P</given-names></name><name><surname>Bauersachs</surname><given-names>J</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Swedberg</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mineralocorticoid receptor antagonists for heart failure with reduced
ejection fraction: integrating evidence into clinical practice</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><issue>22</issue><fpage>2782</fpage><lpage>2795</lpage><pub-id pub-id-type="pmid">22942339</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettencourt </surname><given-names>P</given-names></name><name><surname>Azevedo</surname><given-names>A</given-names></name><name><surname>Pimenta</surname><given-names>J</given-names></name><name><surname>Frioes</surname><given-names>F</given-names></name><name><surname>Ferreira</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name></person-group><article-title>N-terminal-pro-brain natriuretic peptide predicts outcome after
hospital discharge in heart failure patients</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>15</issue><fpage>2168</fpage><lpage>2174</lpage><pub-id pub-id-type="pmid">15451800</pub-id></element-citation></ref></ref-list></back></article>